A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated Dose, Multicentre Phase IIa Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2017
At a glance
- Drugs BT 063 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Proof of concept
- Sponsors Biotest AG
- 11 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2018.
- 11 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.